Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 10913154 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Smits VA, et al. (2000) p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J Biol Chem 275, 30638-43 10913154
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T14-p - CDK1 (human)
Orthologous residues
CDK1 (human): T14‑p, CDK1 (mouse): T14‑p, CDK1 (rat): T14‑p, CDK1 (chicken): T14‑p, CDK1 (fruit fly): T14‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphopeptide mapping, western blotting
 Disease tissue studied:  bone cancer
 Relevant cell lines - cell types - tissues:  U2OS (bone cell), UTA21.15
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
camptothecin increase

Y15-p - CDK1 (human)
Orthologous residues
CDK1 (human): Y15‑p, CDK1 (mouse): Y15‑p, CDK1 (rat): Y15‑p, CDK1 (chicken): Y15‑p, CDK1 (fruit fly): Y15‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphopeptide mapping, western blotting
 Disease tissue studied:  bone cancer
 Relevant cell lines - cell types - tissues:  U2OS (bone cell), UTA21.15
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole decrease
camptothecin increase

T161-p - CDK1 (human)
Orthologous residues
CDK1 (human): T161‑p, CDK1 (mouse): T161‑p, CDK1 (rat): T161‑p, CDK1 (chicken): T161‑p, CDK1 (fruit fly): T161‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, phospho-antibody, phosphopeptide mapping, western blotting
 Disease tissue studied:  bone cancer
 Relevant cell lines - cell types - tissues:  U2OS (bone cell), UTA21.15
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK7 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
camptothecin decrease
p21Cip1 (human) decrease


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.